News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Allison Betof Warner: Relativity-048 presented by Paolo A. Ascierto at ASCO24
Photo taken from Allison Betof Warner/X
Jun 2, 2024, 09:37

Allison Betof Warner: Relativity-048 presented by Paolo A. Ascierto at ASCO24

Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford Cancer Institute, recently posted on X:

“We’ve been waiting for this one!!

RELATIVITY-048 (ipilimumab 1Q8wi and nivolumab and relatimab) presented by Paolo A. Ascierto.

ORR 52% by BICR. Clinical benefit rate 76%. 50% discontinuation due to toxicity.

Allison Betof Warner

Responses in poor prognosis disease.

7/14 with liver metastasis and 2/3 with brain metastasis responded. More to come on brian mets with this combination!

Allison Betof Warner

Rate of G3/4 TRAE is a 39%…actually significantly better than full dose ipilimumab and nivolumab.”

Source: Allison Betof Warner/X

 

Allison Betof Warner ASCO ASCO24 brain metastasis cancer ipilimumab Liver metastasis nivolumab OncoDaily Oncology Paolo A. Ascierto relatimab Stanford Cancer Institute
Special Coverage
Voices
Aug 15, 2025, 19:27
Michael Chuong: Exciting Developments in RT for Pancreatic Cancer
Voices
Aug 15, 2025, 16:15
Theodoros Teknos: Case Comprehensive Cancer Center Awarded $25.5M NCI Cancer Center Support Grant
Science
Aug 15, 2025, 16:10
Saheli Sadanand: Excited to Share a New Cancer Vaccine Study in Nature Medicine
Voices
Aug 15, 2025, 16:00
Amy C Moore Highlights Persistent Challenges in Lung Cancer Survival and Research
Voices
Aug 15, 2025, 15:57
David Heredia Highlighted New Research on Membrane Targets in RET+ NSCLC
Voices
Aug 15, 2025, 15:57
Stephen Liu: Proud to Co-chair The 2026 Texas Lung Cancer Conference with Dr. Tina Cascone
Voices
Aug 15, 2025, 15:57
Minhua Chu: KRAS G12D Inhibitor GFH375 Delivers Strong Responses in NSCLC
Voices
Aug 15, 2025, 15:55
Gender Norms and Barriers Driving Cancer Deaths in West Africa - UICC
Voices
Aug 15, 2025, 15:51
Ruben Mesa: Grateful to Take on a New role as President, Advocate Health Cancer National Service Line
Voices
Aug 15, 2025, 15:48
Annie Wong: Congrats Dr Ros Poulgrain for Presenting New Zealand Clinicians’ Perspective on IO Toxicity Management
Voices
Aug 15, 2025, 15:48
Christopher Fitzmaurice: Study Shows Exercise Benefits in Cancer Surgery Recovery
Voices
Aug 15, 2025, 15:39
Semiramida Nina Markosyan: In Oncology Research, Timing Can Change Everything